These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17666035)

  • 1. Correlates of placebo response in the treatment of sexual dysfunction in women: a preliminary report.
    Bradford A; Meston C
    J Sex Med; 2007 Sep; 4(5):1345-51. PubMed ID: 17666035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo response in the treatment of women's sexual dysfunctions: a review and commentary.
    Bradford A; Meston CM
    J Sex Marital Ther; 2009; 35(3):164-81. PubMed ID: 19360517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genital and subjective measurement of the time course effects of an acute dose of testosterone vs. placebo in postmenopausal women.
    Heard-Davison A; Heiman JR; Kuffel S
    J Sex Med; 2007 Jan; 4(1):209-217. PubMed ID: 17233787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sensitivity of event logs, self-administered questionnaires and photoplethysmography to detect treatment-induced changes in female sexual arousal disorder (FSAD) diagnosis.
    Rellini A; Meston C
    J Sex Med; 2006 Mar; 3(2):283-91. PubMed ID: 16490021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD).
    Orri M; Abraham L; Giraldi A
    J Sex Med; 2013 Oct; 10(10):2484-96. PubMed ID: 23347610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
    Diamond LE; Earle DC; Heiman JR; Rosen RC; Perelman MA; Harning R
    J Sex Med; 2006 Jul; 3(4):628-638. PubMed ID: 16839319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial.
    Muin DA; Wolzt M; Marculescu R; Sheikh Rezaei S; Salama M; Fuchs C; Luger A; Bragagna E; Litschauer B; Bayerle-Eder M
    Fertil Steril; 2015 Sep; 104(3):715-23.e4. PubMed ID: 26151620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating components of sexual well-being in women: are sexual satisfaction and sexual distress independent constructs?
    Stephenson KR; Meston CM
    J Sex Med; 2010 Jul; 7(7):2458-68. PubMed ID: 20456625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial.
    Goldstein I; Fisher WA; Sand M; Rosen RC; Mollen M; Brock G; Karlin G; Pommerville P; Bangerter K; Bandel TJ; Derogatis LR;
    J Sex Med; 2005 Nov; 2(6):819-32. PubMed ID: 16422806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.
    Kingsberg S; Shifren J; Wekselman K; Rodenberg C; Koochaki P; Derogatis L
    J Sex Med; 2007 Jul; 4(4 Pt 1):1001-8. PubMed ID: 17627745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo.
    Clayton AH; Reddy S; Focht K; Musgnung J; Fayyad R
    J Sex Med; 2013 Mar; 10(3):768-76. PubMed ID: 22905811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of body awareness on sexual arousal in women with sexual dysfunction.
    Seal BN; Meston CM
    J Sex Med; 2007 Jul; 4(4 Pt 1):990-1000. PubMed ID: 17627744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
    Clayton AH; Althof SE; Kingsberg S; DeRogatis LR; Kroll R; Goldstein I; Kaminetsky J; Spana C; Lucas J; Jordan R; Portman DJ
    Womens Health (Lond); 2016 Jun; 12(3):325-37. PubMed ID: 27181790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Female sexual satisfaction and pharmaceutical intervention: a critical review of the drug intervention studies in female sexual dysfunction.
    Nijland E; Davis S; Laan E; Schultz WW
    J Sex Med; 2006 Sep; 3(5):763-777. PubMed ID: 16942521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavior and symptom change among women treated with placebo for sexual dysfunction.
    Bradford A; Meston CM
    J Sex Med; 2011 Jan; 8(1):191-201. PubMed ID: 20849412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of women's sexual desire: the role of psychopathology, cognitive-emotional determinants, relationship dimensions, and medical factors.
    Carvalho J; Nobre P
    J Sex Med; 2010 Feb; 7(2 Pt 2):928-37. PubMed ID: 19912503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lady Prelox® improves sexual function in post-menopausal women.
    Bottari A; Belcaro G; Ledda A; Cesarone MR; Vinciguerra G; Di Renzo A; Stuard S; Dugall M; Pellegrini L; Errichi S; Gizzi G; Ippolito E; Ricci A; Cacchio M; Ruffini I; Fano F; Hosoi M
    Panminerva Med; 2012 Dec; 54(1 Suppl 4):3-9. PubMed ID: 23241929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons and correlations of 1-month recall vs 24-hour recall in patient-reported outcomes of an exploratory, phase 2b, randomized, double-blind, placebo-controlled clinical trial of sildenafil cream, 3.6% for the treatment of female sexual arousal disorder.
    Johnson I; Thurman AR; Cornell KA; Symonds T; Hatheway J; Friend DR; Goldstein A
    J Sex Med; 2024 Sep; 21(9):787-792. PubMed ID: 39059373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.
    Basson R; McInnes R; Smith MD; Hodgson G; Koppiker N
    J Womens Health Gend Based Med; 2002 May; 11(4):367-77. PubMed ID: 12150499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.